Medesis Pharma S.A.
Clinical-stage biotech developing treatments using its AONYS® drug delivery platform.
ALMDP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010844464
- LEI:
- 969500C15M96P00UR648
- Country:
- France
- Address:
- AVENUE DU GOLF, 34670 BAILLARGUES
- Website:
- https://www.medesispharma.com/
- Sector:
- Manufacturing
Description
Medesis Pharma is a clinical-stage pharmaceutical biotechnology company focused on developing treatments for serious diseases using its proprietary AONYS® drug delivery platform. The AONYS® technology is a micro-emulsion designed for buccal (oral) administration, enabling the intracellular delivery of various therapeutic molecules, including metal ions, interfering RNAs, and peptides. A key feature of the platform is its ability to transport active ingredients across the blood-brain barrier, making it a promising approach for neurological disorders. The company's development pipeline addresses diseases with high unmet medical needs, including neurodegenerative conditions like Alzheimer's disease and therapies for individuals exposed to nuclear radiation.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-11-28 18:00 |
MEDESIS PHARMA PRÉSENTE UN POSTER SCIENTIFIQUE À LA CONFÉRENCE CLINICAL TRIALS …
|
French | 456.6 KB | ||
| 2022-11-21 18:00 |
MEDESIS PHARMA ANNOUNCES THE CONSTITUTION OF A PERMANENT SCIENTIFIC ADVISORY BO…
|
English | 630.4 KB | ||
| 2022-11-21 18:00 |
MEDESIS PHARMA ANNONCE LA CRÉATION D’UN CONSEIL SCIENTIFIQUE PERMANENT D’EXPERT…
|
French | 757.9 KB | ||
| 2022-10-25 08:00 |
MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS DU 1ER SEMESTRE 2022
|
French | 1020.2 KB | ||
| 2022-10-25 08:00 |
MEDESIS PHARMA : RAPPORT FINANCIER SEMESTRIEL 2022
|
French | 2.7 MB | ||
| 2022-10-04 08:00 |
MEDESIS PHARMA RENFORCE SA GOUVERNANCE
|
French | 881.4 KB | ||
| 2022-10-04 08:00 |
MEDESIS PHARMA FURTHER STRENGTHENS ITS GOVERNANCE
|
English | 717.7 KB | ||
| 2022-07-20 08:00 |
MEDESIS PHARMA receives a grant from AFM-TELETHON to finance the first phases o…
|
English | 537.7 KB | ||
| 2022-07-20 08:00 |
MEDESIS PHARMA reçoit une subvention de l’AFM-TELETHON pour financer les premiè…
|
French | 631.2 KB | ||
| 2022-07-07 18:00 |
MEDESIS PHARMA : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE
|
French | 1.1 MB | ||
| 2022-06-13 08:00 |
MEDESIS PHARMA : TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM FIRST INCLU…
|
English | 567.7 KB | ||
| 2022-06-13 08:00 |
MEDESIS PHARMA : TRAITEMENT DE LA MALADIE D’ALZHEIMER AVEC LE NANOLITHIUM : PRE…
|
French | 681.2 KB | ||
| 2022-06-02 17:45 |
MEDESIS PHARMA - Information mensuelle relative au nombre total des droits de v…
|
French | 222.4 KB | ||
| 2022-05-24 18:00 |
MEDESIS PHARMA : ASSEMBLEE GENERALE MIXTE DU 13 JUIN 2022 - Modalités de mise …
|
French | 296.1 KB | ||
| 2022-04-21 18:30 |
MEDESIS PHARMA - RAPPORT FINANCIER ANNUEL 2021
|
French | 1.9 MB |
Automate Your Workflow. Get a real-time feed of all Medesis Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Medesis Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Medesis Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-16 | N/A | Other | Sell | 1,000 | 1,170.00 EUR |
| 2024-01-18 | N/A | Other | Sell | 800 | 669.60 EUR |
| 2023-07-21 | N/A | Other | Sell | 1,000 | 1,400.00 EUR |
| 2023-07-04 | N/A | Other | Sell | 5,000 | 7,100.00 EUR |
| 2023-05-23 | N/A | Other | Sell | 3,140 | 6,908.00 EUR |
Peer Companies
